Lead Product(s) : KL1333
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Abliva receives positive FDA feedback on its KL1333 development plant
Details : KL1333 is a potent modulator of the cellular levels of NAD, a central co-enzyme in the cell’s energy metabolism. The clinical KL1333 development plan will target patients with genetically confirmed MIDD-MELAS or KSS-CPEO spectrum disorders with multi-o...
Product Name : KL1333
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 07, 2020
Lead Product(s) : KL1333
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable